Solid Phase III data for peg-Avonex should strengthen Biogen's MS position
This article was originally published in Scrip
Executive Summary
Biogen Idec revealed data from the Phase III ADVANCE clinical trial for peginterferon beta-1 on 24 January that should help the company retain its dominance in the treatment of multiple sclerosis with a less frequently dosed version of its market-leading Avonex (interferon beta-1a) - a once-weekly intramuscular injection.